WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey
WHF
WHF COVID-19 and Cardiovascular Disease Survey
1 other identifier
observational
5,200
16 countries
31
Brief Summary
A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Typical duration for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 1, 2020
CompletedFirst Posted
Study publicly available on registry
July 17, 2020
CompletedStudy Start
First participant enrolled
September 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedJanuary 27, 2023
January 1, 2023
1.3 years
July 1, 2020
January 25, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (9)
Assessment of the patients for major adverse cardiovascular events (MACE)
MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure \[including Left ventricular ejection fraction\], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.
Outcome will be assessed at discharge and 30-day follow-up visit from the hospital admission date.
Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]
Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.
at discharge and 30-day follow-up visits from the hospital admission date.
Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)
Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.
at discharge and 30-day follow-up visits from the hospital admission date.
All cause deaths
Specific causes of death to be evaluated using CRF including sudden cardiac death, death due to Myocardial infarction, Death due to heart failure, death due to stroke
any time during the hospital admission and at 30-day follow-up.
Impact of COVID-19 vaccination on clinical outcomes - MACE (major adverse cardiovascular events) in COVID-19 hospitalized patients.
MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure \[including Left ventricular ejection fraction\], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.
upto 30 days
Persistence of long-COVID Symptoms at 1-month after discharge among survivors of COVID-19 hospitalizations.
Questionnaires will be administered telephonically at 1-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.
1-month after hospital discharge
Persistence of long-COVID Symptoms at 3-month after discharge among survivors of COVID-19 hospitalizations.
Questionnaires will be administered telephonically at 3-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.
3-month after hospital discharge
Persistence of long-COVID Symptoms at 6-month after discharge among survivors of COVID-19 hospitalizations.
Questionnaires will be administered telephonically at 6-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.
6-month after hospital discharge
Persistence of long-COVID Symptoms at 9-12-month after discharge among survivors of COVID-19 hospitalizations.
Questionnaires will be administered telephonically at 9-12-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.
9-12-month after hospital discharge
Eligibility Criteria
Participants will be recruited in any hospital where COVID19 patients are hospitalized. Investigators will invite all WHF members from 100+ countries to identify at least two recruiting centres in their respective countries. Each centre should recruit between 50 and 200 consecutive patients. There is no limit in the number of sites to take part.
You may qualify if:
- All adults (as locally defined) with confirmed COVID-19 infection who are hospitalized are eligible.
You may not qualify if:
- Patients for whom investigators are unable to obtain informed consent will be excluded.
- Patients who are unlikely to stay in the recruiting centre for 30 days (i.e. likely to be transferred)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Public Health Foundation of Indialead
- Centre for Chronic Disease Control, Indiacollaborator
- University of Cape Towncollaborator
- World Heart Federation, Geneva, Switzerlandcollaborator
Study Sites (32)
Hospital de Clinicas of the University
Buenos Aires, Argentina
Sanatorio Güemes Hospital
Buenos Aires, Argentina
Bangladesh Specialized Hospital (BSH)
Dhaka, Bangladesh
Dhaka Medical College Hospital (DMCH)
Dhaka, Bangladesh
DNCC Dedicated COVID-19 Hospital
Dhaka, Bangladesh
Kurmitola General Hospital (KGH)
Dhaka, Bangladesh
Kuwait Bangladesh Friendship Hospital
Dhaka, Bangladesh
Popular Medical College Hospital (PMCH)
Dhaka, Bangladesh
University Clinical Center Republic of Srpska
Srpska, Bosnia and Herzegovina
Clinica del Occidente, Columbia
Bogotá, Colombia
Fundacion Valle del Lili
Cali, Colombia
Komfo Anokye Teaching Hospital
Kumasi, Ghana
Kumasi South Regional Hospital
Kumasi, Ghana
Dayanand medical college hospital
Ludhiana, Punjab, India
AIIMS, New Delhi
Delhi, India
Apollo Medical College, Jubilee Hills, Hyderabad, India
Hyderabad, India
Apollol Hopsital,
Hyderabad, India
AIIMS Jodhpur
Jodhpur, India
Amin Hospital
Isfahan, Iran
Khorshid Hospital
Isfahan, Iran
Kyoto Medical Center
Kyoto, Japan
National Hospital Organization Kyoto Medical Center, Japan
Kyoto, Japan
CGTRH-MOMBASA, Kenya
Mombasa, Kenya
UMMC
Kuala Lumpur, Malaysia
ISSSTE Clinica Hospital, Guanajuato
Guanajuato City, Mexico
University College Hospital, Nigeria
Ibadan, Nigeria
Olabisi Onabanjo University Teaching Hospital (OOUTH)
Sagamu, Nigeria
Tabba Heart Institute
Karachi, Sindh, Pakistan
University Hospital Sta Maria, Portugal
Lisbon, Portugal
Groote Schuur Hospital, South Africa
Cape Town, South Africa
Fedail Hospital
Khartoum, Sudan
Levy Mwanawasa University Hospital, Zambia
Lusaka, Zambia
Related Publications (28)
Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016 Jun 1;1(3):274-81. doi: 10.1001/jamacardio.2016.0433.
PMID: 27438105BACKGROUNDMadjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW 3rd. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007 May;28(10):1205-10. doi: 10.1093/eurheartj/ehm035. Epub 2007 Apr 17.
PMID: 17440221BACKGROUNDHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
PMID: 31986264BACKGROUNDGuan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
PMID: 32109013BACKGROUNDZheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
PMID: 32139904BACKGROUNDYang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
PMID: 32173574BACKGROUNDMadjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286.
PMID: 32219363BACKGROUNDKwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090.
PMID: 29365305BACKGROUNDOudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x. Epub 2009 May 6.
PMID: 19453650BACKGROUNDShi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
PMID: 32211816BACKGROUNDGuo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
PMID: 32219356BACKGROUNDLippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 May-Jun;63(3):390-391. doi: 10.1016/j.pcad.2020.03.001. Epub 2020 Mar 10. No abstract available.
PMID: 32169400BACKGROUNDYang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA Cardiol. 2020 Jul 1;5(7):743-744. doi: 10.1001/jamacardio.2020.0934. No abstract available.
PMID: 32211809BACKGROUNDInciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi: 10.1001/jamacardio.2020.1096.
PMID: 32219357BACKGROUNDRibeiro AH, Ribeiro MH, Paixao GMM, Oliveira DM, Gomes PR, Canazart JA, Ferreira MPS, Andersson CR, Macfarlane PW, Meira W Jr, Schon TB, Ribeiro ALP. Automatic diagnosis of the 12-lead ECG using a deep neural network. Nat Commun. 2020 Apr 9;11(1):1760. doi: 10.1038/s41467-020-15432-4.
PMID: 32273514BACKGROUNDAlkmim MB, Silva CBG, Figueira RM, Santos DVV, Ribeiro LB, da Paixao MC, Marcolino MS, Paiva JC, Ribeiro AL. Brazilian National Service of Telediagnosis in Electrocardiography. Stud Health Technol Inform. 2019 Aug 21;264:1635-1636. doi: 10.3233/SHTI190571.
PMID: 31438267BACKGROUNDThienemann F, Pinto F, Grobbee DE, Boehm M, Bazargani N, Ge J, Sliwa K. World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries. Glob Heart. 2020 Apr 9;15(1):31. doi: 10.5334/gh.778.
PMID: 32489804RESULTWu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
PMID: 32091533RESULTLi B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11.
PMID: 32161990RESULTZhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
PMID: 32171076RESULTFang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. No abstract available.
PMID: 32171062RESULTSmeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004 Dec 16;351(25):2611-8. doi: 10.1056/NEJMoa041747.
PMID: 15602021RESULTAlsahafi AJ, Cheng AC. The epidemiology of Middle East respiratory syndrome coronavirus in the Kingdom of Saudi Arabia, 2012-2015. Int J Infect Dis. 2016 Apr;45:1-4. doi: 10.1016/j.ijid.2016.02.004. Epub 2016 Feb 10.
PMID: 26875601RESULTAlhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016 Jan-Feb;36(1):78-80. doi: 10.5144/0256-4947.2016.78.
PMID: 26922692RESULTPrabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T, Sarrafzadegan N, Talukder SH, Akter S, Amin MR, Goma F, Gomez-Mesa J, Ntusi N, Inofomoh F, Deora S, Philippov E, Svarovskaya A, Konradi A, Puentes A, Ogah OS, Stanetic B, Issa A, Thienemann F, Juzar D, Zaidel E, Sheikh S, Ojji D, Lam CSP, Ge J, Banerjee A, Newby LK, Ribeiro ALP, Gidding S, Pinto F, Perel P, Sliwa K; WHF COVID-19 Study Collaborators. Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. Glob Heart. 2022 Jun 15;17(1):40. doi: 10.5334/gh.1128. eCollection 2022.
PMID: 35837356RESULTSliwa K, Singh K, Raspail L, Ojji D, Lam CSP, Thienemann F, Ge J, Banerjee A, Newby LK, Ribeiro ALP, Gidding S, Pinto F, Perel P, Prabhakaran D. The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. Glob Heart. 2021 Apr 19;16(1):22. doi: 10.5334/gh.950.
PMID: 34040935RESULTThienemann F, Chakafana G, Pineiro D, Pinto FJ, Perel P, Singh K, Eisele JL, Prabhakaran D, Sliwa K. WHF Position Statement on COVID Vaccination. Glob Heart. 2021 Apr 27;16(1):29. doi: 10.5334/gh.1027.
PMID: 34040942RESULTPrabhakaran D, Perel P, Roy A, Singh K, Raspail L, Faria-Neto JR, Gidding SS, Ojji D, Hakim F, Newby LK, Stepinska J, Lam CSP, Jobe M, Kraus S, Chuquiure-Valenzuela E, Pineiro D, Khaw KT, Bahiru E, Banerjee A, Narula J, Pinto FJ, Wood DA, Sliwa K. Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. Glob Heart. 2020 Jul 1;15(1):44. doi: 10.5334/gh.823.
PMID: 32923338RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
KAREN SILWA, MD, PhD
University of Cape Town
- PRINCIPAL INVESTIGATOR
Pablo PEREL, MD, PhD
London School of Hygiene and Tropical Medicine
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
July 1, 2020
First Posted
July 17, 2020
Study Start
September 1, 2020
Primary Completion
December 30, 2021
Study Completion
December 31, 2023
Last Updated
January 27, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF, ANALYTIC CODE
- Time Frame
- Two years after study completion and publication of main study results i.e., Dec 2023
- Access Criteria
- Two years after study completion and publication of main study results i.e., Dec 2023, and upon request from external researchers being sent to the study PIs and study steering committee for review and approval
Below is the detail of the data to be collected from each patient enrolled in the study: * Patient demographics: age, sex, ethnicity, weight/height and education level * Clinical history: smoking status, hypertension, diabetes, obesity, heart failure, rheumatic heart disease, chagas, history of Coronary artery disease/ Percutaneous Coronary Interventions/ Coronary artery bypass graft surgery * Usual medication (before hospitalization) * Clinical characteristics at presentation: confirmed diagnosis of COVID-19, heart rate, blood pressure * Tests: ECG, ECHO, troponin, NT-proBNP and other biochemical markers * Medication received during hospitalization: cardiovascular and non-cardiovascular medications.